A:NYE-Agilent Technologies Inc. (USD)

EQUITY | Diagnostics & Research | New York Stock Exchange

Last Closing

USD 134.6

Change

+0.09 (+0.07)%

Market Cap

USD 14.27B

Volume

1.19M

Analyst Target

USD 102.38
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Agilent Technologies Inc provides application focused solutions that includes instruments, software, services and consumables for the entire laboratory workflow for life sciences, diagnostics and applied chemical markets.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-23 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
DHR Danaher Corporation

+0.61 (+0.27%)

USD 165.08B
IQV IQVIA Holdings Inc

+1.84 (+0.93%)

USD 36.13B
LH Laboratory Corporation of Amer..

-0.77 (-0.34%)

USD 19.12B
DGX Quest Diagnostics Incorporated

-0.16 (-0.10%)

USD 17.09B
QGEN Qiagen NV

+0.15 (+0.34%)

USD 10.26B
CRL Charles River Laboratories

-0.38 (-0.20%)

USD 9.50B
VNRX Volitionrx Ltd

-0.07 (-9.75%)

USD 0.06B
ENZ Enzo Biochem Inc

-0.02 (-2.85%)

USD 0.04B
TMO Thermo Fisher Scientific Inc

+1.24 (+0.24%)

N/A
MTD Mettler-Toledo International I..

+3.65 (+0.30%)

N/A

ETFs Containing A

TECX:CA TD Global Technology Lead.. 99.72 % 0.00 %

-0.10 (0%)

CAD 4.50M
GNOM Global X Genomics & Biote.. 4.37 % 0.00 %

+0.03 (+0%)

USD 0.07B
GN0M:XETRA Global X Genomics & Biote.. 4.06 % 0.00 %

-0.04 (0%)

USD 7.05M
GNOM:SW Global X Genomics & Biote.. 4.06 % 0.00 %

N/A

USD 9.83M
GNOG:LSE Global X Genomics & Biote.. 4.06 % 0.00 %

+0.01 (+0%)

USD 9.08M
XGEN:XETRA Xtrackers MSCI Genomic He.. 3.91 % 0.00 %

-0.14 (0%)

N/A
XGES:LSE Xtrackers MSCI Genomic He.. 3.85 % 0.00 %

-0.01 (0%)

N/A
EDOC:SW Global X Telemedicine & D.. 3.82 % 0.00 %

N/A

N/A
ABIE:XETRA AXA IM ACT Biodiversity E.. 2.41 % 0.00 %

-0.08 (0%)

N/A
ABIT:XETRA AXA IM ACT Biodiversity E.. 2.19 % 0.00 %

-0.06 (0%)

N/A
ROIS 0.94 % 0.00 %

N/A

N/A
FIW First Trust Water ETF 0.00 % 0.55 %

-0.25 (0%)

N/A
HIG:CA Global Healthcare Income .. 0.00 % 1.02 %

+0.08 (+0%)

CAD 0.05B
GOAT 0.00 % 0.00 %

N/A

N/A
HHL-U:CA Harvest Healthcare Leader.. 0.00 % 0.00 %

+0.03 (+0%)

N/A
DRDR:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

-0.25 (0%)

N/A
TOCA:CA TD One-Click Aggressive E.. 0.00 % 0.00 %

N/A

CAD 0.13B
TOCC:CA TD One-Click Conservative.. 0.00 % 0.00 %

N/A

CAD 0.04B
TOCM:CA TD One-Click Moderate ETF.. 0.00 % 0.00 %

N/A

CAD 0.08B
MJJ 0.00 % 0.00 %

N/A

N/A
MJO 0.00 % 0.00 %

N/A

N/A
EDOC Global X Telemedicine & D.. 0.00 % 0.00 %

-0.10 (0%)

USD 0.04B
HHL-B:CA Harvest Healthcare Leader.. 0.00 % 0.00 %

+0.04 (+0%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.19% 38% F 27% F
Dividend Return 0.51% 57% F 6% D-
Total Return -2.68% 38% F 23% F
Trailing 12 Months  
Capital Gain -3.56% 38% F 26% F
Dividend Return 0.68% 57% F 7% C-
Total Return -2.88% 38% F 22% F
Trailing 5 Years  
Capital Gain 57.80% 75% C 77% C+
Dividend Return 4.90% 80% B- 12% F
Total Return 62.70% 83% B 75% C
Average Annual (5 Year Horizon)  
Capital Gain 14.23% 69% C- 74% C
Dividend Return 14.90% 92% A 71% C-
Total Return 0.67% 86% B+ 17% F
Risk Return Profile  
Volatility (Standard Deviation) 29.05% 62% D 37% F
Risk Adjusted Return 51.30% 92% A 66% D+
Market Capitalization 14.27B 89% A- 95% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Diagnostics & Research) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 31.90 63% 22%
Price/Book Ratio 6.80 22% 14%
Price / Cash Flow Ratio 22.90 22% 15%
Price/Free Cash Flow Ratio 22.49 33% 15%
Management Effectiveness  
Return on Equity 24.66% 100% 89%
Return on Invested Capital 29.28% 89% 94%
Return on Assets 7.58% 100% 88%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector